158 related articles for article (PubMed ID: 37622544)
61. Management of low-grade dysplasia in Barrett's esophagus.
Wani S
Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
Wang Y; Ma B; Yang S; Li W; Li P
Front Oncol; 2022; 12():801940. PubMed ID: 35296005
[TBL] [Abstract][Full Text] [Related]
63. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
64. A Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.
Lee C; Hayat U; Song K; Gravely AA; Mesa H; Peltola J; Iwamoto C; Manivel C; Bilal M; Shaheen N; Shaukat A; Hanson BJ
Dis Esophagus; 2023 Feb; 36(3):. PubMed ID: 36190180
[TBL] [Abstract][Full Text] [Related]
65. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial.
Vennalaganti PR; Kaul V; Wang KK; Falk GW; Shaheen NJ; Infantolino A; Johnson DA; Eisen G; Gerson LB; Smith MS; Iyer PG; Lightdale CJ; Schnoll-Sussman F; Gupta N; Gross SA; Abrams J; Haber GB; Chuttani R; Pleskow DK; Kothari S; Goldblum JR; Zhang Y; Sharma P
Gastrointest Endosc; 2018 Feb; 87(2):348-355. PubMed ID: 28757316
[TBL] [Abstract][Full Text] [Related]
66. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study.
Sinh P; Anaparthy R; Young PE; Gaddam S; Thota P; Balasubramanian G; Singh M; Higbee AD; Wani S; Gupta N; Rastogi A; Mathur SC; Bansal A; Horwhat JD; Cash BD; Falk GW; Lieberman DA; Vargo JJ; Sampliner RE; Sharma P
Endoscopy; 2015 Aug; 47(8):669-74. PubMed ID: 25910065
[TBL] [Abstract][Full Text] [Related]
67. A Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients With Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results From Q-TAB.
Peabody JW; Cruz JDC; Ganesan D; Paculdo D; Critchley-Thorne RJ; Wani S; Shaheen NJ
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00644. PubMed ID: 37767993
[TBL] [Abstract][Full Text] [Related]
68. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
[TBL] [Abstract][Full Text] [Related]
69. Not all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.
Tsoi EH; Williams RA; Christie M; Machet D; Deb S; Sundararajan V; Cameron GR; Desmond PV; Taylor ACF
Pathology; 2021 Oct; 53(6):700-704. PubMed ID: 34420794
[TBL] [Abstract][Full Text] [Related]
70. Endoscopic therapy of esophageal premalignancy and early malignancy.
Nealis TB; Washington K; Keswani RN
J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
[TBL] [Abstract][Full Text] [Related]
71. Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals.
Nieuwenhuis EA; van Munster SN; Curvers WL; Weusten BLAM; Alvarez Herrero L; Bogte A; Alkhalaf A; Schenk BE; Koch AD; Spaander MCW; Tang TJ; Nagengast WB; Westerhof J; Houben MHMG; Bergman JJGHM; Schoon EJ; Pouw RE;
Endoscopy; 2022 Oct; 54(10):936-944. PubMed ID: 35098524
[TBL] [Abstract][Full Text] [Related]
72. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.
Eluri S; Brugge WR; Daglilar ES; Jackson SA; Styn MA; Callenberg KM; Welch DC; Barr TM; Duits LC; Bergman JJ; Shaheen NJ
Am J Gastroenterol; 2015 Jun; 110(6):828-34. PubMed ID: 26010308
[TBL] [Abstract][Full Text] [Related]
73. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
74. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis.
Chandrasekar VT; Hamade N; Desai M; Rai T; Gorrepati VS; Jegadeesan R; Sathyamurthy A; Sharma P
Endoscopy; 2019 Jul; 51(7):665-672. PubMed ID: 30939618
[TBL] [Abstract][Full Text] [Related]
75. Risk of progression of Barrett's esophagus in patients with cirrhosis.
Apfel T; Lopez R; Sanaka MR; Thota PN
World J Gastroenterol; 2017 May; 23(18):3287-3294. PubMed ID: 28566888
[TBL] [Abstract][Full Text] [Related]
76. Clinical prediction model for tumor progression in Barrett's esophagus.
Holmberg D; Ness-Jensen E; Mattsson F; Lagergren J
Surg Endosc; 2019 Sep; 33(9):2901-2908. PubMed ID: 30456503
[TBL] [Abstract][Full Text] [Related]
77. Somatic DNA copy number alterations in non-dysplastic Barrett's esophagus.
Callahan ZM; Liu W; Hou J; Zheng SL; Rehman J; Hedberg HM; Brown CS; Su B; Attaar M; Kuchta K; Regner M; Carbray J; Xu J; Ujiki M
Surg Endosc; 2021 Jul; 35(7):3961-3970. PubMed ID: 32749611
[TBL] [Abstract][Full Text] [Related]
78. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
79. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review.
Wani S; Puli SR; Shaheen NJ; Westhoff B; Slehria S; Bansal A; Rastogi A; Sayana H; Sharma P
Am J Gastroenterol; 2009 Feb; 104(2):502-13. PubMed ID: 19174812
[TBL] [Abstract][Full Text] [Related]
80. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
